GSK, Amgen and AstraZeneca tout Phase 3 data in inflammatory nasal condition
GSK, Amgen and AstraZeneca released positive data supporting their rival drugs in a condition called chronic rhinosinusitis with nasal polyps, or CRSwNP. GSK’s depemokimab and Amgen and AstraZeneca’s Tezspire both met the co-primary endpoints in ...
GSK, Amgen and AstraZeneca released positive data supporting their rival drugs in a condition called chronic rhinosinusitis with nasal polyps, or CRSwNP.
GSK’s depemokimab and Amgen and AstraZeneca’s Tezspire both met the co-primary endpoints in ...
